Reported results
- Cash and cash equivalents were $247.7 million as of September 30, 2026.
- Research and development (R&D) expenses were $9.3 million for the three months ended September 30, 2026.
- General and administrative (G&A) expenses were $4.9 million for the three months ended September 30, 2026.
- Net loss was $12.4 million, or $0.08 basic and diluted net loss per share for the three months ended September 30, 2026.
- Total outstanding shares were 186,609,073 ordinary shares as of September 30, 2026.
Notes
The company entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany, which is expected to close in the first quarter of 2027.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.
